Skip to main content
Year archive

AFT Pharmaceuticals Limited — 2021 filings

All 39 regulatory filings released by AFT Pharmaceuticals Limited (AFT) in 2021, sourced directly from the official regulator.

39 Filings
2021 Period
2021 filings (39)
Filing Released Lang
Disclosure of Directors and Senior Managers Relevant Intere
Director's Dealing
2021-12-22 English
AFT welcomes Australian Federal Court appeal success
Legal Proceedings Report
2021-12-09 English
Amended Capital Change Notice – Issue of ordinary shares
Share Issue/Capital Change
2021-12-08 English
Capital Change Notice – Issue of ordinary shares
Capital/Financing Update
2021-12-07 English
re-issued FY22H1 Presentation
Investor Presentation
2021-11-17 English
AFT reaffirms guidance and progresses growth plan
Interim / Quarterly Report
2021-11-17 English
FDA confirms earlier than expected PDUFA date for Maxigesic
Regulatory Filings
2021-11-14 English
AFT appoints McPherson’s as Singapore distributor
Regulatory Filings
2021-11-04 English
US FDA accepts Maxigesic IV(R) New Drug Application
Capital/Financing Update
2021-10-31 English
Maxigesic IV(R) registered in the UK and Ireland
Regulatory Filings
2021-10-18 English
interim results announcement on Thursday November 18 2021
Report Publication Announcement
2021-10-11 English
AFT further extends Maxigesic(R) footprint; strengthens EU
Capital/Financing Update
2021-09-20 English
Capital Change Notice – Issue of ordinary shares
Share Issue/Capital Change
2021-09-06 English
Results of ASM 2021
Declaration of Voting Results & Voting Rights Announcements
2021-08-06 English
ASM Presentation and Chair’s address
AGM Information
2021-08-05 English
New clinical study – Novaliq NovaTears(R)+Omega-3 eye drops
Regulatory Filings
2021-07-28 English
D&O Ongoing Disclosure – Louise Clayton
Director's Dealing
2021-07-14 English
Capital Change Notice – Issue of ordinary shares
Share Issue/Capital Change
2021-07-14 English
Maxigesic(R) Oral Liquid gets first regulatory approval
Regulatory Filings
2021-07-13 English
ASM 2021 Proxy form
AGM Information
2021-07-07 English
Maxigesic(R) IV launches in Germany and Austria
Regulatory Filings
2021-07-07 English
Notice of Annual Meeting of Shareholders 2021
AGM Information
2021-07-05 English
Capital Change Notice – Issue of ordinary shares
Share Issue/Capital Change
2021-06-21 English
Annual Report
Annual Report
2021-05-26 English
Annual Meeting and Closing Date for Director Nominations
AGM Information
2021-05-26 English
AFT delivers growth amid global disruptions
Annual Report
2021-05-23 English
AFT extends Maxigesic(R) IV license in South America
Capital/Financing Update
2021-05-04 English
AFT results announcement May 24 2021
Report Publication Announcement
2021-05-03 English
Capital Change Notice – Issue of ordinary shares
Share Issue/Capital Change
2021-05-03 English
AFT licenses Maxigesic(R) IV in the US
Capital/Financing Update
2021-04-27 English
D&O Ongoing Disclosure – Louise Clayton
Director's Dealing
2021-04-13 English
D&O Ongoing Disclosure – Malcolm Tubb
Director's Dealing
2021-04-13 English
Capital Change Notice – Issue of ordinary shares
Share Issue/Capital Change
2021-04-13 English
Crystawash(R) Extend distribution in UAE, Kuwait, Oman and Ke
Regulatory Filings
2021-04-11 English
AFT secures new partners in Poland and Greece
Capital/Financing Update
2021-04-06 English
AFT updates earnings guidance
Earnings Release
2021-03-31 English
AFT licenses Pascomer(R) for Europe
Regulatory Filings
2021-03-16 English
Maxigesic(R) IV licensed in eight new European markets
Capital/Financing Update
2021-03-04 English
24-hour efficacy for Crystawash Extend Hand Sanitiser
Regulatory Filings
2021-01-10 English